BEAM - JP Morgan upgrades Beam to overweight cites AATD therapy potential
2024-01-29 14:48:44 ET
More on Beam Therapeutics
- CRISPR Gene Editing: Beam Therapeutics
- Beam Therapeutics: Sale Of Rights To Verve's In Vivo Candidates An Odd Decision
- Biotechs post record gains in November amid improving outlook
- Gene editing stocks slide after two-day rally
- Seeking Alpha’s Quant Rating on Beam Therapeutics